Clinical trial results released by Wave Life Sciences Wednesday appear to provide early validation for the company’s newest drugmaking technology as well as a burgeoning field of genetic medicine, RNA ...

WVE-006 is the first-ever RNA editing program to enter clinical development and is designed to restore production and circulation of functional, wild-type alpha-1 antitrypsin (AAT) protein and reduce ...

CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people ...

Presentations include new data showing WVE-006 improved markers of liver disease in mice; WVE-006 is a first-in-class RNA editing therapeutic for alpha-1 antitrypsin deficiency (AATD) which is ...

Wave Life Sciences Ltd. (NASDAQ: WVE) is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. The company is generating ...

Wave Life Sciences specializes in oligonucleotide therapeutics, leveraging its RNA editing platform to develop treatments for a variety of genetic disorders. The company’s approach aims to provide ...

Achieved proof-of-mechanism for Wave’s RNA editing platform; restoring levels of wild-type (edited) M-AAT that are consistent with the heterozygous “MZ” genotype with low risk of AATD lung and liver ...

Wave Life Sciences Ltd. (NASDAQ:WVE) stock is trading higher on Wednesday after the company revealed proof-of-mechanism data from the ongoing Phase 1b/2a RestorAATion-2 study of WVE-006 in alpha-1 ...

Wave Life Sciences Ltd . (NASDAQ:WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, has been making significant ...

CRISPR/Cas9 genome editing has captured the attention of the popular media, the scientific community and the investment world: The promise of going into a cell and precisely making changes in its ...

Chemistry optimization yields a four-fold increase over PBS control in AAT protein restoration in vivo preclinically (or more than 15 micromolar) CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- ...